US Stock Market Movement: Charles River surged on October 5th, reaffirmed guidance, 2030 target, and CRO.

Charles River October 5th: Major Surge Analysis

Keywords: Reiterated Guidance, 2030 Target, CRO

1. On September 24th, the company reiterated its fiscal year 2026 guidance at Investor Day, expecting revenue and non-GAAP earnings per share to be at the upper end of the previously provided range. The company is primarily engaged in contract research services, offering drug discovery, development, and safety testing services for pharmaceutical and biotechnology firms.

2. On September 24th, the company announced its long-term goal through 2030, projecting an organic revenue compound annual growth rate of 5%–7%, and plans to save over $300 million cumulatively from 2027 to 2030 through the "Create the Future" project.

3. On September 25th, several institutions raised their target prices for Charles River: Deutsche Bank increased to $320, RBC to $322, Evercore ISI to $330, Baird to $334, and TD Cowen to $325.

(Disclaimer: This content is generated by AI based on publicly available information and is for reference only. It does not constitute investment advice.)